Printer Friendly

Peptimmune obtains exclusive license from Genzyme to develop and commercialize treatment for metabolic diseases including obesity.

Genzyme Corporation (Cambridge, MA) and Peptimmune, Inc. announced that Genzyme has granted an exclusive worldwide license to Peptimmune to develop and market a Genzyme investigational drug candidate for the treatment of obesity and other metabolic disease indications. Peptimmune plans to file an IND with the United States Food and Drug Administration to begin clinical trials of the drug later this year.

Under the agreement, Genzyme grants Peptimmune exclusive rights to develop, manufacture and commercialize GT389-255, in exchange for royalties, in addition to shared milestones and payments if the program is partnered further. Financial details were not disclosed.

"The acquisition of a product in the metabolic disease field that could enter the clinic in 2004 broadens and diversifies Peptimmune's pipeline," stated Tom Mathers, president of Peptimmune. "It accelerates our evolution from a research and discovery stage company, to a fully integrated biopharmaceutical company. The prospect of a new treatment for obesity offers hope for the millions of people suffering from this worldwide epidemic."

The investigational drug candidate, GT389-255, has a dual mechanism of action, serving as a pancreatic lipase inhibitor and a fat-binder. It acts within the gastro-intestinal tract to prevent fat digestion and is expected to have fewer side-effects than currently marketed therapies. GT389-255 has been evaluated in a number of preclinical studies, including investigational new drug-enabling toxicology studies.

"We have discovered a very innovative treatment for obesity that has the potential to address a very serious and growing worldwide public health problem," stated Ted Sybertz, Ph.D., senior vice president and general manager of Genzyme Drug Discovery and Development. "However, because of its broad physician call-point, obesity is not a strategic fit for Genzyme. Given Peptimmune's experienced management team, clinical development expertise in both autoimmune and metabolic disease, and their commitment to moving this program forward, we think they are an excellent partner."

The Genzyme drug discovery effort that developed the anti-obesity program has drawn upon the company's extensive expertise in developing compounds to treat metabolic disease and its world-renowned reputation in polymer chemistry. Two polymer products have been brought to market, Renagel (sevelamer hydrochloride), a calcium-free, metal-free phosphate binder for patients with end-stage renal disease, and WelChol (colesevelum hydrocholoride), a cholesterol-lowering agent. A third polymer, tolevamer, has recently completed Phase 2 clinical trials for the treatment of C. difficile associated diarrhea. These polymer therapies are not absorbed and all act within the GI tract.

Obesity is a global healthcare issue that is associated with an increased risk of serious metabolic diseases, including cardiovascular disease, Type 2 diabetes, hypertension, stroke, dyslipidemia, and osteoarthritis. Published prevalence rates indicate that more than 180 million people in the United States and Europe are obese, and the number of obese individuals continues to increase dramatically worldwide. A 1999 article published in the Journal of the American Medical Association estimates that there are some 300,000 deaths per year in the United States that are attributed to overweight and obesity. According to data released by the United States Department of Health and Human Services, the direct medical costs to the United States population that were attributed to obesity totaled $117 billion in 2000.

Genzyme is a global biotechnology company dedicated to making a major positive impact on the lives of people with serious diseases. The company's broad product portfolio is focused on rare genetic disorders, renal disease, osteoarthritis and immune-mediated diseases, and includes an industry-leading array of diagnostic products and services. Genzyme's commitment to innovation continues today with research into novel approaches to cancer, heart disease, and other areas of unmet medical need. More than 6,300 Genzyme employees in offices around the globe serve patients in over 80 countries.

Peptimmune is a privately held biotechnology company focused on development of therapeutics for the treatment of autoimmune and metabolic diseases. Peptimmune has one product in clinical trials for the treatment of pemphigus vulgaris, and a pipeline of late stage preclinical products for the treatment of autoimmune and metabolic diseases including, multiple sclerosis, rheumatoid arthritis and obesity.

Genzyme +1-617-768-6690

Peptimmune +1-617-715-8009
COPYRIGHT 2004 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Geographic Code:1USA
Date:Jun 1, 2004
Previous Article:Introgen Therapeutics receives patent for purified adenoviral compositions.
Next Article:Galenica acquisition finalized.

Related Articles
Genzyme receives broad patent covering gene therapy for Fabry disease.
Amgen and Biovitrum sign metobolic disease license agreement.
Genzyme Genetics licenses colon cancer diagnostic.
Peptimmune obtains exclusive license from Genzyme to develop and commercialize treatment for metabolic diseases including obesity.
Genzyme files suit against TKT for glucocerebrosidase patent infringement.
Genzyme signs licensing agreement with UCLA cancer center to develop CML markers.
Lexicon expands alliance with Genentech to discover and develop biotherapeutic drugs.
Schering-Plough licenses worldwide rights to pradefovir, oral hepatitis B treatment in development with Valeant and Metabasis.
Genzyme and Isis Form Alliance for High Risk Cardiovascular Patients.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters